Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
1970
1.1K+
LTM Revenue $259M
LTM EBITDA $49.3M
$566M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, Lumibird reported last 12-month revenue of $259M and EBITDA of $49.3M.
In the same period, Lumibird achieved $16.7M in LTM net income.
See Lumibird valuation multiples based on analyst estimatesIn the most recent fiscal year, Lumibird reported revenue of $243M and EBITDA of $35.9M.
Lumibird expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Lumibird valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $259M | XXX | $243M | XXX | XXX | XXX |
Gross Profit | n/a | XXX | $151M | XXX | XXX | XXX |
Gross Margin | n/a | XXX | 62% | XXX | XXX | XXX |
EBITDA | $49.3M | XXX | $35.9M | XXX | XXX | XXX |
EBITDA Margin | 19% | XXX | 15% | XXX | XXX | XXX |
EBIT | $28.2M | XXX | $17.2M | XXX | XXX | XXX |
EBIT Margin | 11% | XXX | 7% | XXX | XXX | XXX |
Net Profit | $16.7M | XXX | $6.6M | XXX | XXX | XXX |
Net Margin | 6% | XXX | 3% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $89.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lumibird has current market cap of EUR 449M (or $520M), and EV of EUR 489M (or $566M).
As of October 17, 2025, Lumibird's stock price is EUR 20 (or $24).
See Lumibird trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$566M | $520M | XXX | XXX | XXX | XXX | $0.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialLumibird's trades at 2.3x EV/Revenue multiple, and 15.7x EV/EBITDA.
See valuation multiples for Lumibird and 15K+ public compsAs of October 17, 2025, Lumibird has market cap of $520M and EV of $566M.
Equity research analysts estimate Lumibird's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lumibird has a P/E ratio of 31.2x.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $520M | XXX | $520M | XXX | XXX | XXX |
EV (current) | $566M | XXX | $566M | XXX | XXX | XXX |
EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
EV/EBITDA | 11.5x | XXX | 15.7x | XXX | XXX | XXX |
EV/EBIT | 20.1x | XXX | 32.8x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | 31.2x | XXX | 78.9x | XXX | XXX | XXX |
EV/FCF | 33.0x | XXX | 42.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLumibird's last 12 month revenue growth is 9%
Lumibird's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Lumibird's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lumibird's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lumibird and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
EBITDA Margin | 19% | XXX | 15% | XXX | XXX | XXX |
EBITDA Growth | 21% | XXX | 28% | XXX | XXX | XXX |
Rule of 40 | 23% | XXX | 24% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
Healius | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lumibird acquired XXX companies to date.
Last acquisition by Lumibird was XXXXXXXX, XXXXX XXXXX XXXXXX . Lumibird acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Lumibird founded? | Lumibird was founded in 1970. |
Where is Lumibird headquartered? | Lumibird is headquartered in France. |
How many employees does Lumibird have? | As of today, Lumibird has 1.1K+ employees. |
Is Lumibird publicy listed? | Yes, Lumibird is a public company listed on PAR. |
What is the stock symbol of Lumibird? | Lumibird trades under LBIRD ticker. |
When did Lumibird go public? | Lumibird went public in 1997. |
Who are competitors of Lumibird? | Similar companies to Lumibird include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
What is the current market cap of Lumibird? | Lumibird's current market cap is $520M |
What is the current revenue of Lumibird? | Lumibird's last 12 months revenue is $259M. |
What is the current revenue growth of Lumibird? | Lumibird revenue growth (NTM/LTM) is 9%. |
What is the current EV/Revenue multiple of Lumibird? | Current revenue multiple of Lumibird is 2.2x. |
Is Lumibird profitable? | Yes, Lumibird is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Lumibird? | Lumibird's last 12 months EBITDA is $49.3M. |
What is Lumibird's EBITDA margin? | Lumibird's last 12 months EBITDA margin is 19%. |
What is the current EV/EBITDA multiple of Lumibird? | Current EBITDA multiple of Lumibird is 11.5x. |
What is the current FCF of Lumibird? | Lumibird's last 12 months FCF is $17.1M. |
What is Lumibird's FCF margin? | Lumibird's last 12 months FCF margin is 7%. |
What is the current EV/FCF multiple of Lumibird? | Current FCF multiple of Lumibird is 33.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.